ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.

Autres langues Asymchem Laboratories (Tianjin) Co., Ltd.

Actions

002821

CNE100002BZ6

Produits pharmaceutiques

Cours en clôture Shenzhen S.E. 20/08/2026			Varia. 5j.	Varia. 1 janv.
182,40 ^CNY	+6,92%		+4,94%	+96,28%

31/07	Asymchem Laboratories va souscrire à l'augmentation de capital de sa filiale pour 1,05 milliard de yuans ; le titre grimpe de 6 %	MT
27/07	AsymBio, filiale du groupe Asymchem, lance la construction d'un centre de R&D à Fengxian	CI

Autres langues

31/07	Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6%
30/07	Shanghai Asymchem Biotechnology Development Co., Ltd. announced that it expects to receive CNY 1.239699995 billion in funding from Asymchem Laboratories Co., Ltd., Suzhou Gao Ling Qirui Healthcare Investment, L.P. and another investor
27/07	AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building
11/06	Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026
27/05	AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
27/05	AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
27/05	Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
20/05	Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says
15/05	Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026
13/05	Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 5.36% on May 7, HKEX says
04/05	JPMorgan Chase's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 7.64% on Apr 28 from 8.18%, HKEX filing shows
28/04	Asymchem Laboratories' Profit Falls 6.8% in Q1; Shares Rise 8%
27/04	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Asymchem Laboratories (Tianjin) Q1 net profit down 6.8% Y/Y
21/04	Asymchem Laboratories Profit Rises 19% in 2025
14/04	Asymchem Unveils Fully Integrated TIDES Commercial Supply Matrix
30/03	Asymchem Laboratories (Tianjin) 2025 net profit up 19.4% Y/Y
30/03	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
30/03	Asymchem Laboratories Co., Ltd. announces Annual dividend, payable on June 26, 2026
09/03	AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03	AsymBio Completes Dual-Site One-Center Network With Fengxian Commercial Manufacturing Site Operational
25/02	Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) increases to 11.67% on Feb 19 from 9.34%, HKEX filing shows
22/12	Asymchem Laboratories Cuts Buyback Price Under 2025 Share Scheme; Shares
08/12	Asymbio Commences Commercial Operations At Fengxian Base, Strengthening Global Biopharmaceutical Cdmo Capabilities
30/10/25	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025